Top

Tag: cell therapy


Cell and Gene Therapy, Industry, Mergers and Acquisitions

AstraZeneca Acquires Neogene, Expanding in Cancer Cell Therapy

November 30, 2022

Via: GEN

AstraZeneca has agreed to acquire Neogene Therapeutics for up to $320 million cash, the companies said Tuesday, in a deal intended to bolster the buyer’s portfolio of cancer-fighting cell therapies. Neogene specializes in discovering, developing, and manufacturing next-generation T-cell receptor […]


Cell and Gene Therapy, Industry

AstraZeneca reveals its cell therapy ambitions with deal for startup

November 29, 2022

Via: Biopharma Dive

Once a fringe area of cancer research, cell therapy has exploded over the last decade. Since 2017, several treatments have come to market for blood cancers like leukemia and multiple myeloma, establishing cell therapy as a new class of medicines. […]


Cell and Gene Therapy, Industry

Mainstreaming cell and gene therapy – Realizing its potential

November 28, 2022

Via: Biopharma Dive

Brief overview of the CGT landscape A useful starting point is to understand the different types of CGTs. The following are the definition of the three types: Cell therapies: involves the transfer of intact, live cells into a patient to […]


Cell and Gene Therapy, Industry

Modular plug-and-produce facilities for cell therapies

November 7, 2022

Via: Biopharma Dive

At the start of 2021, a crane lifted a shrink-wrapped, elongated structure off a truck flatbed and through a window into an upper floor of Shanghai’s ATLATL Innovation Center. Two months later, that structure was a full-fledged facility for the […]


News

Nucleome raises £37.5m to shine light on ‘dark genome’

October 19, 2022

Via: Pharmaphorum

The dark genome – a loose term that covers non-coding regions of the genome that are capable of regulating the expression of genes, previously rather inaccurately referred to as junk DNA – is increasingly being explored by biopharma companies for […]


Cell and Gene Therapy, Industry

‘In vivo’ cell therapy: expanding beyond CAR-T

October 18, 2022

Via: Biopharma Dive

In 2011, cancer cell therapy was closer to science project than treatment. Immunologist Carl June and his colleagues at the University of Pennsylvania were struggling to raise money for a small study of a cell therapy for leukemia. The trial […]


Mergers and Acquisitions

Gamma Biosciences, Lonza Enter Cell and Gene Therapy Alliance

October 14, 2022

Via: Contract Pharma

Gamma Biosciences, a provider of tools and technologies for cell and gene therapy manufacturing, through their BioMagnetic Solutions business, entered a strategic collaboration with Lonza. Under the multi-year agreement, BioMagnetic Solutions will supply its research and cGMP manufacturing grade FerroSelect […]


Mergers and Acquisitions

Showa Denko Materials, Kidswell Bio Enter Cell Therapy Alliance

October 14, 2022

Via: Contract Pharma

Showa Denko Materials Co., Ltd. and Kidswell Bio Corp. have entered an agreement to enable process development and clinical manufacturing of cell therapy products using the advantage of SHED*2 (Stem cells from Human Exfoliated Deciduous teeth) which is under development […]


Cell and Gene Therapy, FDA, Industry, Regulations

FDA Expands Oversight of Cell and Gene Therapies

October 12, 2022

Via: Biopharm International

FDA’s Center for Biologics Evaluation and Research (CBER) is updating how it manages a growing volume of cellular and gene therapy development programs, seeking added resources and revisions in its oversight of these cutting-edge therapies. Most visible in the elevation […]


Cell and Gene Therapy, Industry

Cellusion, Minaris Enter LOI for Manufacturing Process for Cell Therapy

October 12, 2022

Via: Contract Pharma

Cellusion, a Japanese regenerative medicine startup, and Minaris Regenerative Medicine, a global CDMO, announced Letter of Intent (LOI) for the manufacturing of CLS001 for a Corneal Endothelial Cell Regenerative therapy in the U.S. The companies will develop the manufacturing process […]


Cell and Gene Therapy, Clinical Trials, Industry, Research and Development

Allogene starts first pivotal trials of an ‘off-the-shelf’ cell therapy for cancer

October 7, 2022

Via: Biopharma Dive

Allogene Therapeutics has begun the first pivotal test of an “off-the-shelf” cell therapy for cancer. The biotechnology company, which has been at the forefront of a push in recent years to develop such treatments, known as allogeneic therapies and derived […]


Cell and Gene Therapy, Industry

A Flagship cell therapy startup secures $120M in new funding

October 4, 2022

Via: Biopharma Dive

Cellarity has raised $120 million in its third round of venture financing, bringing the company’s total funding raised since launching in 2017 to $293 million. The funds will be used to bring Cellarity’s first research programs into clinical testing for […]


Cell and Gene Therapy, Clinical Trials, Industry, Research and Development

Vertex, CRISPR prep filing for gene-editing blood disorder therapy

September 28, 2022

Via: Pharmaphorum

The rolling application for exagamglogene autotemcel (exa-cel) – formerly known as CTX001 – will start in November, while a filing in Europe is also expected by the end of the year, said the two partners. The time places exa-cel in […]


Mergers and Acquisitions

Roche puts $70m into ArsenalBio’s programmable T-cell platform

September 28, 2022

Via: Pharmaphorum

Genentech is providing $70 million in funding for the multi-year project, which is aimed at identifying “critical success circuits” in T cell therapies used to treat cancer, along with undisclosed milestone payments. A key focus of the alliance is to […]


Cell and Gene Therapy, Industry, Mergers and Acquisitions

GenScript and Avectas Partner on Next-Generation Cell Therapies

September 22, 2022

Via: GEN

GenScript and Avectas agreed to partner to develop an improved non-viral cell therapy manufacturing process. By combining Avectas’ cell engineering technology with GenScript’s expertise in synthetic long oligo production, the partnership aims to demonstrate a novel and efficient solution for […]


Cell and Gene Therapy, Industry, Mergers and Acquisitions

GenScript and Avectas link up to improve non-viral cell therapy processes

September 20, 2022

Via: Pharma Times

GenScript – the life-sciences research tools and services provider – and Avectas, a cell engineering technology company, are partnering to develop an improved non-viral cell therapy manufacturing process. The two companies are focusing on new methods for developing cell therapies […]


Cell and Gene Therapy, Industry

Ori Biotech Partners with the Cell Therapy Manufacturing Center to Accelerate Cell Therapy Delivery

September 13, 2022

Via: Contract Pharma

Ori Biotech, a leader in cell and gene therapy (CGT) manufacturing technologies, and the Cell Therapy Manufacturing Center (CTMC), a joint venture between National Resilience Inc. and MD Anderson Cancer Center, have entered a collaborative partnership to develop industrial manufacturing […]


News

A history of blood cancer treatment

September 13, 2022

Via: Pharmaphorum

Over the past two centuries, researchers have identified more than 100 different types of blood cancer, while most patients may be familiar with the big three (leukaemia, lymphoma, and melanoma). However, myelodysplastic syndromes and myeloproliferative neoplasms are also prominent types […]


Cell and Gene Therapy, Industry

Stem cell-gene therapy shows promise in ALS safety trial

September 5, 2022

Via: World Pharma News

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This combined stem cell and gene therapy can potentially protect diseased motor neurons in the spinal cord of […]


Mergers and Acquisitions

Novo Nordisk steps up sickle cell push with $1.1bn Forma buy

September 2, 2022

Via: Pharmaphorum

The $20-per-share agreement was a premium of 92% over Forma’s closing share price yesterday, but its stock leaped after the deal was announced from $13.40 to just under the deal price. The biotech went public via a $278 million IPO […]